Natco Pharma declares ₹1.50 interim dividend, re-appoints key management
Natco Pharma declared a third interim dividend of ₹1.50 per share for FY26. The Board re-appointed Chairman & MD, Vice Chairman & CEO, and other key directors for one year from April 1, 2026. Amit Parekh appointed as CFO. Consolidated revenue was ₹705.4 crore, net profit ₹151.3 crore for Q3FY26.
The interim dividend and re-appointment of key management are positive developments, and the financial results are solid, but there are no major strategic shifts or exceptionally high growth figures that would indicate a high impact.
The declaration of an interim dividend, re-appointment of key management, and positive financial results contribute to a positive sentiment.
Natco Pharma Limited announced the outcome of its Board Meeting held on February 12, 2026. The Board approved the unaudited financial results for the quarter and nine months ended December 31, 2025, both on a standalone and consolidated basis.
The company declared a third interim dividend of ₹1.50 per equity share for the financial year 2025-26. The record date for this dividend has been fixed as February 18, 2026, with payments commencing from February 26, 2026.
Furthermore, the Board re-appointed several key directors for a period of one year effective April 1, 2026. These include Sri Venkaiah Chowdary Nannapaneni as Chairman & Managing Director, Sri Rajeev Nannapaneni as Vice Chairman & Chief Executive Officer, Sri Potluri Sivaramakrishna Prasad as Director and Executive Vice President (Corporate Engineering Services), and Dr. Donthineni Linga Rao as Director & President (Tech. Affairs). These re-appointments are subject to shareholder approval via postal ballot.
The Board also noted the superannuation of the Chief Financial Officer, Mr. S. V. V. N. Appa Rao, effective February 12, 2026. Subsequently, Mr. Amit Parekh, Executive Vice President – Finance & Accounts, has been appointed as the new Chief Financial Officer, effective February 13, 2026.
Additionally, the company approved the incorporation of a wholly-owned subsidiary in Chile, NATCO Pharma Chile SPA, with an investment not exceeding US$ 3,00,000 (₹2.48 crore). The Board also approved the re-constitution of the Environmental, Social and Governance (ESG) Committee and Risk Management Committee, effective February 13, 2026.
The financial results for the quarter ended December 31, 2025, showed consolidated total revenue of ₹705.4 crore and a net profit of ₹151.3 crore. The consolidated EBITDA margin was reported at 30.7%. The company also reported segmental revenues, with Formulations export contributing ₹421.4 crore, followed by Domestic Formulations at ₹119.8 crore.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.